Zithromax®
azithromycin · oral tablet
Antibiotic
Approved uses
Systemic bacterial infection, this label's only approved uses: acute bacterial exacerbation of chronic bronchitis, acute bacterial sinusitis, community-acquired pneumonia, second-line pharyngitis or tonsillitis, uncomplicated skin and skin structure infection, urethritis and cervicitis, genital ulcer disease in men, and pediatric acute otitis media
Adults, 500 mg on day 1 then 250 mg once daily on days 2 through 5 (community-acquired pneumonia, pharyngitis or tonsillitis, skin and skin structure, or acute bacterial exacerbation of chronic bronchitis), or 500 mg once daily for 3 days (acute bacterial exacerbation of chronic bronchitis or acute bacterial sinusitis); one single 1 gram dose for non-gonococcal urethritis or cervicitis and chancroid, one single 2 gram dose for the gonococcal form; pediatric acute otitis media 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg on day 1 then 5 mg/kg/day on days 2 through 5
OFF-LABELNot in the FDA label for this product
Trachoma, individual treatment and community mass drug administration
Single oral dose of 20 mg/kg
RCT · n=64 · Cochrane moderate
In a randomized controlled trial of 64 patients with active trachoma, a single 20 mg/kg oral dose resolved disease in 63.3% versus 65.4% treated with 6 weeks of topical tetracycline ointment, with no significant difference between groups and no adverse events noted. A 2019 Cochrane review found moderate-certainty evidence for mass treatment: one low risk of bias cluster-randomized study in high-prevalence communities showed reduced active trachoma 12 months after a single dose (RR 0.58, 95% CI 0.52 to 0.65), and two pooled studies showed reduced ocular infection at 12 months (RR 0.36, 95% CI 0.31 to 0.43), against high-certainty evidence of roughly five-fold increased resistance of Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli at 12 months.
Posterior blepharitis and meibomian gland dysfunction
500 mg on day 1 then 250 mg once daily on days 2 through 5, repeated for three cycles separated by 5-day intervals
RCT · n=30 · oral subgroup NS
A randomized comparative trial of 30 patients, 15 per arm, found this oral course and topical azithromycin 1.5% both improved Ocular Surface Disease Index, lissamine green staining and Schirmer scores, while the topical arm held cytologic improvement at least 5 weeks and produced longer tear break-up time. A 2020 systematic review and meta-analysis of 18 studies found pooled symptom scores improved with azithromycin overall (SMD 1.54, 95% CI 1.15 to 1.92), but the oral subgroup alone did not reach significance for tear break-up time (P=0.08) or corneal staining (P=0.14); the pooled adverse event rate was 7% for oral and 25% for topical.
Contraindications
- Known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide drug
- History of cholestatic jaundice or hepatic dysfunction on prior exposure to this drug
250 mg tablets, bottles of 30, Z-PAKS of 6, unit dose 50; 500 mg tablets, bottles of 30, TRI-PAKS of 3; oral suspension 100 or 200 mg/5 mL
Macrolide that binds the 23S rRNA of the 50S ribosomal subunit, inhibiting bacterial protein synthesis and impeding assembly of the 50S subunit. Active against Chlamydia trachomatis, the organism of trachoma and inclusion conjunctivitis, and cross-resistant with erythromycin.
Warnings & Precautions
- Hypersensitivity: Serious allergic reactions, including angioedema, anaphylaxis, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported, with fatalities; DRESS has also been reported. In some patients allergic symptoms recurred soon after symptomatic therapy was stopped, without further drug exposure, and these patients required prolonged observation. If an allergic reaction occurs, discontinue the drug and institute appropriate therapy.
- Hepatotoxicity: Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis and hepatic failure, some resulting in death; discontinue immediately if signs or symptoms of hepatitis appear.
- QT prolongation: Torsades de pointes reported in postmarketing surveillance; weigh the risk, which can be fatal, in patients with known QT prolongation, prior torsades, congenital long QT syndrome, bradyarrhythmias, uncompensated heart failure, on drugs known to prolong the QT interval, with uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or on Class IA or Class III antiarrhythmics. Elderly patients may be more susceptible.
- Cardiovascular death: Some observational studies show an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults versus other antibacterials including amoxicillin; five-day cardiovascular mortality was 20 to 400 per million treatment courses. This potential risk was greater in the first five days and does not appear limited to preexisting cardiovascular diseases. The data are insufficient to establish or exclude causation. Consider balancing it with treatment benefits.
- Infantile hypertrophic pyloric stenosis: Reported after use in neonates treated up to 42 days of life. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs.
- Clostridioides difficile-associated diarrhea: May range from mild diarrhea to fatal colitis and has been reported over two months after antibacterial use. Consider it in all patients with diarrhea after antibiotic use. If suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued; institute fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation as clinically indicated.
- Myasthenia gravis exacerbation: Symptom exacerbation and new onset of myasthenic syndrome reported during therapy.
- Syphilis masking: At the recommended dose this drug should not be relied upon to treat syphilis, and agents used to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and testing for gonorrhea at diagnosis, with appropriate antibacterial therapy and follow-up tests if infection is confirmed.
- Development of drug-resistant bacteria: Prescribing in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Common Side Effects
- Ocular: Conjunctivitis, reported at 1% or less in pediatric trials.
- Special senses, postmarketing: Hearing disturbance including hearing loss, deafness and tinnitus, and taste or smell perversion or loss.
- Systemic: Diarrhea 5 to 14%, nausea 3 to 18%, abdominal pain 3 to 7%, vomiting 2 to 7%; the top of each range comes from the single 2 gram regimen, which produced nausea 18%, diarrhea 14%, vomiting 7% and abdominal pain 7%.
- Single 1 gram regimen: Diarrhea 7%, nausea 5%, abdominal pain 5%, vomiting 2%, dyspepsia 1%, vaginitis 1%.
- Multiple-dose regimens in adults: Diarrhea or loose stools 4 to 5%, nausea 3%, abdominal pain 2 to 3%, with nothing else above 1%.
- Hepatic: Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis and hepatic failure, some fatal.
- Cardiac, postmarketing: QT prolongation, torsades de pointes, ventricular tachycardia, hypotension and cardiovascular death.
- Skin, postmarketing: Erythema multiforme, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS.
Pregnancy: Published data and postmarketing experience over several decades have not identified drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes; animal studies showed no drug-induced fetal malformations at up to 4 times (rats) and 2 times (mice and rabbits) an adult 500 mg daily dose by body surface area.
Lactation: Present in human milk and still detectable up to 4 weeks after a single 2 gram dose given during labor; non-serious reactions have been reported in breastfed infants, so monitor for diarrhea, vomiting or rash.
Safety and effectiveness have not been established under 6 months of age for acute otitis media, acute bacterial sinusitis and community-acquired pneumonia, or under 2 years of age for pharyngitis/tonsillitis. Use for acute bacterial sinusitis and community-acquired pneumonia in pediatric patients 6 months of age or greater is supported by adequate and well-controlled trials in adults.